Andere Sprachen Curis, Inc.

Aktien

A3ETJD

US2312693094

CRIS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 29.04.2024			% 5 Tage	% 1. Jan.
14,71 ^USD	+1,66 %		-0,94 %	+15,37 %

09.02.	CURIS, INC. : HC Wainwright gibt eine Kauf-Bewertung ab	ZM
08.02.	Curis, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Curis Reports Inducement Grants under NASDAQ Listing Rule 5635(4)	08.04.
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	05.04.
Curis to Present at Upcoming Healthcare Conferences in April	04.04.
Purcell & Lefkowitz LLP Announces Shareholder Investigation of Curis, Inc. (NASDAQ: CRIS)	02.04.
Curis Provides Fourth Quarter 2023 Business Update	09.02.
Curis, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	08.02.
Curis: Q4 Earnings Snapshot	08.02.
Earnings Flash (CRIS) CURIS Reports Q4 Revenue $2.7M, vs. Street Est of $3.1M	08.02.
Curis, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	08.02.
Curis to Release Fourth Quarter 2023 Financial Results and Hold Conference Call on February 8, 2024	01.02.
Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)	05.01.
Curis Announces Initial Combination Study Data from its TakeAim Lymphoma Study	12.12.
Curis, Inc. Announces Initial Combination Study Data from Its Take Aim Lymphoma Study	12.12.
Curis Presented Clinical Data from the TakeAim Leukemia Study at the 2023 ASH Conference	11.12.
Curis Enters into Agreement for Emavusertib, Pembrolizumab Combination Study in Melanoma	06.12.
Curis Announces Three Presentations at ASH	06.12.
Curis Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma	05.12.
Curis, Inc. Enters into Agreement for Emavusertib / Pembrolizumab Combination Study in Melanoma	05.12.
Curis: Q3 Earnings Snapshot	02.11.
Earnings Flash (CRIS) CURIS Posts Q3 Revenue $2.8M, vs. Street Est of $2.6M	02.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Curis, Inc.

Aktien

A3ETJD

US2312693094

CRIS

Andere Sprachen

Filter